论文部分内容阅读
目的评估血清乙肝大蛋白(hepatitis B virus large protein,HBV-LP)在慢性乙型肝炎(chronic hepatitis B,CHB)患者抗病毒治疗中的临床价值。方法经恩替卡韦治疗120例CHB患者,分别于用药0周、12周、24周、36周、48周、72周、96周检测HBVLP、HBV DNA水平。结果在CHB患者中,HBV-LP及HBV DNA检出率比较,差异无统计学意义(P>0.05);在抗病毒治疗中,HBV-LP与HBV DNA降低呈一致趋势,HBV-LP的消减晚于HBV DNA(P<0.05)。结论血清HBV-LP检测是抗病毒疗效评估及治疗终点判断的有效指标。
Objective To evaluate the clinical value of serum hepatitis B virus large protein (HBV-LP) in antiviral therapy in patients with chronic hepatitis B (CHB). Methods 120 CHB patients treated with entecavir were enrolled in this study. HBV DNA and HBV DNA levels were measured at 0, 12, 24, 36, 48, 72 and 96 weeks after treatment. Results There was no significant difference in the detection rate of HBV-LP and HBV DNA in CHB patients (P> 0.05). In the antiviral therapy, HBV-LP and HBV DNA decreased in a consistent trend, and the reduction of HBV-LP Later than HBV DNA (P <0.05). Conclusion Serum HBV-LP test is an effective index for evaluating antiviral efficacy and judging the end of treatment.